Identifies tumor-intrinsic SIRPα's role in immune suppression in melanoma, suggesting therapeutic strategies.
Summary SIRPα is a well-characterized inhibitory receptor on myeloid immune cells. However, human and mouse melanoma cells can also express high levels of SIRPα. Whether and how melanoma cell-intrinsic SIRPα contributes to tumor progression and anti-tumor immunity remains underexplored. Here, we identify a role of tumor cell-intrinsic SIRPα in suppressing immune recruitment and activation. SIRPα deletion in melanoma cells enhances tumor control and increases immune infiltration. Transcriptomic analyses reveal that loss of tumor cell-intrinsic SIRPα upregulates the chemokine CXCL10 in both human and mouse melanoma cells. Notably, Cxcl10 knockdown in SIRPα-deficient melanoma partially rescues tumor growth and reduces CD8⁺ T cell infiltration, mirroring the phenotype of SIRPα-expressing tumors and indicating that tumor cell-intrinsic SIRPα promotes immune evasion by suppressing Cxcl10-mediated T cell recruitment. Our study uncovers an unrecognized mechanism of SIRPα-mediated immune suppression and highlights SIRPα silencing as a potential therapeutic strategy to enhance immune infiltration and T cell-mediated tumor control across SIRPα-expressing cancers.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: